Breaking News, Promotions & Moves

Sonoma Biotherapeutics Names Stephen Dilly as CEO

Dr. Dilly brings nearly forty years of experience and a track record of leadership, business development and drug development.

Author Image

By: Charlie Sternberg

Associate Editor

Sonoma Biotherapeutics Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, has appointed Stephen Dilly, MBBS, PhD, former President and Chief Executive Officer of Codexis Inc., and current Chair of the Codexis Board, as the company’s new President, CEO and member of the Board of Directors. The company also announced that co-founder Jeff Bluestone, PhD, will continue to serve as a member of the Board of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters